This article is more than 5 years old. Information may no longer be current.

Pfizer first quarter revenue down slightly; ophthalmic sales up

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — Pfizer reported first quarter 2006 revenue of $12.66 billion, down slightly from the $13.09 billion reported in the year-ago period, according to a company press release.

Glaucoma medications Xalatan (latanoprost) and Xalacom (timolol and latanoprost) revenue increased 1% to $337 million.

Age-related macular degeneration treatment Macugen (pegaptanib sodium) helped increase the alliance revenue for Pfizer to $324 million, up 34% in the quarter from first quarter 2005.

In addition, the company highlighted the collaboration that began during the quarter with NicOx to identify novel drugs to treat ophthalmic disorders.